Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database
Introduction
Supraventricular tachycardia (SVT) is the most common arrhythmia in infants, with an estimated incidence of 1/250 to 1/1000 among all infants and 1/10 among infants with congenital heart disease (CHD) [1], [2], [3], [4], [5], [6]. Medications used to treat SVT typically fall into one of three categories: 1) abortive therapies; 2) acute management therapies used to achieve rate control or improve the likelihood of arrhythmia abortion; and 3) secondary prevention or “prophylactic” therapies used to prevent SVT recurrence [7], [8]. Across this therapeutic spectrum, over a dozen different therapies are used to treat SVT.
Although a broad armamentarium of therapies is available, there is limited evidence to guide management. Current practices are based on survey data, small clinical trials, and retrospective studies involving few (< 300) infants [7], [9], [10], [11], [12], [13], [14], [15], [16]. There are no Food and Drug Administration (FDA)-labeled medications for SVT in pediatric populations, and the safety profile of commonly used medications has not been well described in infants. This is of particular importance in infants with CHD who are at high risk of adverse events and poor outcomes.
To better understand current practices in SVT management, safety of commonly used medications, and outcomes of hospitalized infants treated for SVT, we conducted a retrospective cohort study using a large database. Results of our study are useful for guiding management and identifying priorities for future clinical trials required for FDA medication labeling.
Section snippets
Database and study cohort
We performed a retrospective cohort study using data generated from electronic medical records (EMR) of infants cared for by clinicians in one of 348 neonatal intensive care units (NICUs) managed by the Pediatrix Medical Group from 1998 to 2012. The data are de-identified and stored in the Pediatrix Clinical Data Warehouse [17]. We included all infants discharged with a diagnosis of SVT who received SVT therapy during their first 120 days of life. SVT diagnosis was based on the clinical
Patient demographics
Of the 887,910 infants present in the database, 2848 (0.3%) infants met our inclusion criteria and were included in this analysis. The median (interquartile range) gestational age and birth weight of the included infants was 37 weeks (34, 38) and 2950 g (2210, 3520). Median postnatal age at diagnosis was 2 days (0, 8), and 1869/2848 (66%) were diagnosed with SVT in the first week of life. Underlying arrhythmia diagnoses included unspecified SVT (2200/2848, 77%), atrial flutter (448/2848, 16%), and
Discussion
This is the largest study to date evaluating treatment practices and in-hospital outcomes of infants with SVT. Overall, SVT in-hospital recurrence was high (13%), and almost one fifth of our cohort experienced an AE while receiving secondary prevention therapy. In addition, we found significant practice variation in medications used to treat SVT. Taken together, these findings suggest that further studies are needed to establish best practices in treatment of SVT in infants to improve outcomes
Conflict of interest
The authors have no potential conflict of interest.
Acknowledgments
Funding disclosure
P.Y.C. and R.H.C. do not have any financial disclosures. National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the National Institute of Child Health and Human Development (HHSN2752010000031 and 1R01-HD081044-01) and the Food and Drug Administration (1R18-FD005292-01); he also receives research support from Cempra Pharmaceuticals (subaward to HHS0100201300009C) and industry for neonatal and pediatric drug
References (27)
- et al.
Electrophysiologic studies of supraventricular tachycardia in children. I. Clinical-electrophysiologic correlations
Am Heart J
(1981) - et al.
Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants
Am Heart J
(1996) - et al.
Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients
J Pediatr
(1997) - et al.
Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants
Am Heart J
(2001) - et al.
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children < 1 year of age
J Am Coll Cardiol
(2002) - et al.
The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system—tools for “meaningful use” in continuous quality improvement
Clin Perinatol
(2010) - et al.
Atrial flutter in infants
J Am Coll Cardiol
(2006) - et al.
Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia
J Am Coll Cardiol
(2005) - et al.
Paroxysmal tachycardia in infants and children: study of 41 cases
Pediatrics
(1952) Paroxysmal tachycardia in infancy: a clinical and experimental study
Acta Paediatr
(1963)